Karolinska Development AB (publ) (KDEV.ST)
SEK 0.94
(2.74%)
SEK 0.94
(2.74%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.56 Million SEK | 13.33% |
| 2022 | 10.2 Million SEK | -92.61% |
| 2021 | 138.18 Million SEK | 53.86% |
| 2020 | 89.81 Million SEK | -43.5% |
| 2019 | 158.97 Million SEK | -68.1% |
| 2018 | 498.37 Million SEK | 25.81% |
| 2017 | 396.13 Million SEK | -3.03% |
| 2016 | 408.5 Million SEK | 11.44% |
| 2015 | 366.57 Million SEK | 465.5% |
| 2014 | 64.82 Million SEK | 155.46% |
| 2013 | 25.37 Million SEK | -86.7% |
| 2012 | 190.8 Million SEK | 10.98% |
| 2011 | 171.93 Million SEK | 204.56% |
| 2010 | 56.45 Million SEK | 40.33% |
| 2009 | 40.23 Million SEK | 204.4% |
| 2008 | 13.21 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 13.13 Million SEK | 13.54% |
| 2024 Q2 | 13.41 Million SEK | 2.11% |
| 2023 Q1 | 7.98 Million SEK | -21.81% |
| 2023 Q3 | 8.47 Million SEK | -12.86% |
| 2023 Q2 | 9.72 Million SEK | 21.84% |
| 2023 Q4 | 11.56 Million SEK | 36.52% |
| 2023 FY | 11.56 Million SEK | 13.33% |
| 2022 Q3 | 10.11 Million SEK | -2.26% |
| 2022 Q4 | 10.2 Million SEK | 0.95% |
| 2022 FY | 10.2 Million SEK | -92.61% |
| 2022 Q1 | 10.33 Million SEK | -92.52% |
| 2022 Q2 | 10.34 Million SEK | 0.1% |
| 2021 Q4 | 138.18 Million SEK | 1.29% |
| 2021 FY | 138.18 Million SEK | 53.86% |
| 2021 Q1 | 88.37 Million SEK | -1.6% |
| 2021 Q2 | 90.84 Million SEK | 2.79% |
| 2021 Q3 | 136.42 Million SEK | 50.18% |
| 2020 Q1 | 123.77 Million SEK | -22.14% |
| 2020 Q2 | 117.99 Million SEK | -4.66% |
| 2020 Q3 | 103.81 Million SEK | -12.02% |
| 2020 Q4 | 89.81 Million SEK | -13.49% |
| 2020 FY | 89.81 Million SEK | -43.5% |
| 2019 FY | 158.97 Million SEK | -68.1% |
| 2019 Q2 | 530.08 Million SEK | 3.19% |
| 2019 Q4 | 158.97 Million SEK | -69.75% |
| 2019 Q1 | 513.69 Million SEK | 3.07% |
| 2019 Q3 | 525.49 Million SEK | -0.87% |
| 2018 Q4 | 498.37 Million SEK | 15.87% |
| 2018 FY | 498.37 Million SEK | 25.81% |
| 2018 Q2 | 416.36 Million SEK | 2.74% |
| 2018 Q3 | 430.12 Million SEK | 3.31% |
| 2018 Q1 | 405.25 Million SEK | 2.3% |
| 2017 Q3 | 383.51 Million SEK | 3.7% |
| 2017 Q4 | 396.13 Million SEK | 3.29% |
| 2017 FY | 396.13 Million SEK | -3.03% |
| 2017 Q1 | 361.61 Million SEK | -11.48% |
| 2017 Q2 | 369.84 Million SEK | 2.28% |
| 2016 FY | 408.5 Million SEK | 11.44% |
| 2016 Q1 | 375.61 Million SEK | 2.46% |
| 2016 Q2 | 383.39 Million SEK | 2.07% |
| 2016 Q4 | 408.5 Million SEK | 3.0% |
| 2016 Q3 | 396.61 Million SEK | 3.45% |
| 2015 Q3 | 357.86 Million SEK | 1.91% |
| 2015 Q1 | 380.79 Million SEK | 487.42% |
| 2015 FY | 366.57 Million SEK | 465.5% |
| 2015 Q4 | 366.57 Million SEK | 2.44% |
| 2015 Q2 | 351.15 Million SEK | -7.78% |
| 2014 Q4 | 64.82 Million SEK | 120.14% |
| 2014 Q2 | 21.21 Million SEK | 5.79% |
| 2014 Q1 | 20.05 Million SEK | -20.95% |
| 2014 Q3 | 29.44 Million SEK | 38.78% |
| 2014 FY | 64.82 Million SEK | 155.46% |
| 2013 Q4 | 25.37 Million SEK | -3.04% |
| 2013 Q2 | 24.12 Million SEK | -1.53% |
| 2013 Q1 | 24.49 Million SEK | -87.16% |
| 2013 FY | 25.37 Million SEK | -86.7% |
| 2013 Q3 | 26.17 Million SEK | 8.49% |
| 2012 Q2 | 165.6 Million SEK | -0.15% |
| 2012 Q1 | 165.85 Million SEK | -3.53% |
| 2012 FY | 190.8 Million SEK | 10.98% |
| 2012 Q4 | 190.8 Million SEK | -13.57% |
| 2012 Q3 | 220.77 Million SEK | 33.31% |
| 2011 FY | 171.93 Million SEK | 204.56% |
| 2011 Q4 | 171.93 Million SEK | 0.0% |
| 2010 FY | 56.45 Million SEK | 40.33% |
| 2009 FY | 40.23 Million SEK | 204.4% |
| 2008 FY | 13.21 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 4.42 Million SEK | -161.387% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 71.686% |
| NextCell Pharma AB | 13.68 Million SEK | 15.487% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 15.994% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.601% |
| AcouSort AB (publ) | 10.37 Million SEK | -11.476% |
| OncoZenge AB (publ) | 1.69 Million SEK | -580.93% |
| Xintela AB (publ) | 14.01 Million SEK | 17.453% |
| Ziccum AB (publ) | 6.38 Million SEK | -81.105% |
| Active Biotech AB (publ) | 13.4 Million SEK | 13.664% |
| Alzinova AB (publ) | 9.33 Million SEK | -23.985% |
| Amniotics AB (publ) | 10.54 Million SEK | -9.69% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 89.147% |
| BioArctic AB (publ) | 139.5 Million SEK | 91.707% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.261% |
| Camurus AB (publ) | 414.81 Million SEK | 97.211% |
| Cantargia AB (publ) | 54.97 Million SEK | 78.954% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -201.433% |
| CombiGene AB (publ) | 4.15 Million SEK | -178.369% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 83.733% |
| Genovis AB (publ.) | 98.04 Million SEK | 88.201% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 37.445% |
| Mendus AB (publ) | 51.22 Million SEK | 77.415% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 39.632% |
| Kancera AB (publ) | 17.97 Million SEK | 35.649% |
| LIDDS AB (publ) | 3.75 Million SEK | -208.014% |
| Lipum AB (publ) | 7.53 Million SEK | -53.476% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -124.292% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 90.669% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -390.42% |
| Saniona AB (publ) | 86.08 Million SEK | 86.561% |
| Simris Alg AB (publ) | 148.93 Million SEK | 92.232% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 83.898% |
| Intervacc AB (publ) | 21.68 Million SEK | 46.637% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 66.566% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 56.683% |
| Corline Biomedical AB | 6.78 Million SEK | -70.408% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 81.145% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 28.219% |
| Aptahem AB (publ) | 8.99 Million SEK | -28.575% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 74.948% |
| Fluicell AB (publ) | 8.91 Million SEK | -29.77% |
| Biovica International AB (publ) | 34.76 Million SEK | 66.724% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 0.848% |
| Abliva AB (publ) | 16.78 Million SEK | 31.059% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 94.609% |
| 2cureX AB (publ) | 2.93 Million SEK | -294.174% |
| I-Tech AB | 16.2 Million SEK | 28.608% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.024% |
| Cyxone AB (publ) | 4.69 Million SEK | -146.464% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 13.198% |
| Biosergen AB | 5.08 Million SEK | -127.512% |
| Nanologica AB (publ) | 79.32 Million SEK | 85.416% |
| SynAct Pharma AB | 51.83 Million SEK | 77.681% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -45.54% |
| BioInvent International AB (publ) | 90.45 Million SEK | 87.21% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -122.697% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 93.629% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -544.872% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 9.22% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -59.353% |